Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PGB-1
- Development stage
- Preclinical
- Modality
- Peptides
- Administration
- Oral, Intraperitoneal
01
Overview
PGB-1 is a novel sulfono-γ-AApeptide foldamer that acts as a peptide inhibitor. It is designed to disrupt the interaction between Protein phosphatase 1 regulatory subunit 3G (PPP1R3G) and protein phosphatase 1γ (PP1γ), thereby blocking Receptor-interacting protein kinase 1 (RIPK1)-dependent tubular cell death and mitigating necroptosis. Preclinical studies indicate its therapeutic potential in reducing graft injury during kidney transplantation and attenuating kidney fibrosis, suggesting its utility for human chronic kidney disease.
02
Targets
PPP1R3G (Protein phosphatase 1 regulatory subunit 3G)RIPK1 (Receptor-interacting serine/threonine-protein kinase 1)
Beyond the preview
Go deeper on PGB-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PGB-1.